Skip to main content
. 2022 Nov 11;7(6):100612. doi: 10.1016/j.esmoop.2022.100612

Table 2.

AEs reported in ≥10% of patients in the alectinib arm (n = 152) of the ALEX study (data cut-off: 29 November 2019)

n (%) TEAEs
TRAEs
Any grade Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Any grade
Any AEs 147 (96.7) 138 (90.8) 112 (73.7) 69 (45.4) 14 (9.2) 7 (4.6) 123 (80.9)
 Constipation 56 (36.8) 47 (30.9) 8 (5.3) 1 (0.7) 0 0 42 (27.6)
 Liver function abnormalities 52 (34.2) 16 (10.5) 22 (14.5) 12 (7.9) 2 (1.3) 0 45 (29.6)
 Anaemia 40 (26.3) 12 (7.9) 19 (12.5) 8 (5.3) 1 (0.7) 0 24 (15.8)
 Fatigue 34 (22.4) 28 (18.4) 4 (2.6) 2 (1.3) 0 0 24 (15.8)
 Peripheral oedema 29 (19.1) 25 (16.4) 4 (2.6) 0 0 0 16 (10.5)
 Myalgia 26 (17.1) 21 (13.8) 5 (3.3) 0 0 0 17 (11.2)
 Nausea 25 (16.4) 20 (13.2) 4 (2.6) 1 (0.7) 0 0 12 (7.9)
 Diarrhoea 24 (15.8) 18 (11.8) 5 (3.3) 1 (0.7) 0 0 11 (7.2)
 Upper respiratory tract infection 21 (13.8) 8 (5.3) 12 (7.9) 1 (0.7) 0 0 0
 Rash 21 (13.8) 16 (10.5) 2 (1.3) 2 (1.3) 1 (0.7) 0 16 (10.5)
 Arthralgia 20 (13.2) 16 (10.5) 3 (2.0) 1 (0.7) 0 0 6 (3.9)
 Back pain 20 (13.2) 12 (7.9) 5 (3.3) 3 (2.0) 0 0 0

AE, adverse event; TEAE, treatment-emergent adverse event; TRAE, treatment-related adverse event.